Pieris Pharmaceuticals, Inc.
Symbol: PIRS
NASDAQ
11.08
USDMarknadspris idag
-0.5788
P/E-tal
0.0000
PEG-kvot
13.70M
MRK Aktiekapital
- 0.00%
DIV Avkastning
{{företagets_namn}} (PIRS) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 174.43 | 26.4 | 59.2 | 117.8 | |||||||||||
balance-sheet.row.short-term-investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.net-receivables | 11.07 | 6 | 5.8 | 3.3 | |||||||||||
balance-sheet.row.inventory | 2.1 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 37.14 | 6.3 | 8.4 | 6.5 | |||||||||||
balance-sheet.row.total-current-assets | 224.75 | 38.7 | 73.4 | 127.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 42.47 | 0 | 20.7 | 23 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0.65 | 0 | 1.4 | 2.9 | |||||||||||
balance-sheet.row.total-non-current-assets | 43.11 | 0 | 22.1 | 25.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.account-payables | 22.5 | 3.4 | 4.2 | 8.6 | |||||||||||
balance-sheet.row.short-term-debt | 14.09 | 0 | 0.9 | 1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 24.12 | 0 | 12.2 | 13.8 | |||||||||||
Deferred Revenue Non Current | 12.49 | 0 | 18.7 | 38.4 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -12.49 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 36.07 | 8.6 | 10.7 | 15.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 36.6 | 0 | 31 | 52.2 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 37.32 | 0 | 12.2 | 13.8 | |||||||||||
balance-sheet.row.total-liab | 154.63 | 11.9 | 67.6 | 102.8 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.37 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -1228.58 | -315 | -290.4 | -257.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.87 | 0 | -0.3 | 0.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1342.3 | 341.6 | 318.5 | 307 | |||||||||||
balance-sheet.row.total-stockholders-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 267.86 | - | - | - | |||||||||||
Total Investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.total-debt | 37.32 | 0 | 13.1 | 13.8 | |||||||||||
balance-sheet.row.net-debt | -97.65 | -17.4 | -25.5 | -103.9 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1.81 | 1.8 | 2.8 | 2.4 | |||||||||||
cash-flows.row.deferred-income-tax | 14.53 | -4.5 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 3.35 | 3.3 | 4.4 | 5.2 | |||||||||||
cash-flows.row.change-in-working-capital | -48.14 | -48.1 | -33.4 | 30.5 | |||||||||||
cash-flows.row.account-receivables | 5.31 | 5.3 | -2.6 | -1.8 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 5.7 | |||||||||||
cash-flows.row.account-payables | -0.79 | -0.8 | -4.2 | 7 | |||||||||||
cash-flows.row.other-working-capital | -12.71 | -52.7 | -26.5 | 19.6 | |||||||||||
cash-flows.row.other-non-cash-items | -0.82 | 18.3 | -0.5 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -53.82 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.acquisitions-net | -12.17 | 0 | 20.2 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -22.84 | -22.8 | -48.4 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 35.01 | 35 | 28.2 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 12.17 | 0 | -20.2 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 12 | 12 | -21.2 | -0.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -1 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 19.74 | 19.8 | 6.9 | 57.1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.07 | 0.1 | 1.3 | 2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 19.8 | 19.8 | 7.2 | 59.1 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.78 | 0.8 | -5.2 | -3.2 | |||||||||||
cash-flows.row.net-change-in-cash | -21.24 | -21.2 | -79.1 | 47.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 134.97 | 17.4 | 38.6 | 117.8 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 156.21 | 38.6 | 117.8 | 70.4 | |||||||||||
cash-flows.row.operating-cash-flow | -53.82 | -53.8 | -59.9 | -7.7 | |||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.free-cash-flow | -53.99 | -54 | -61 | -8.6 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 42.81 | 42.8 | 25.9 | 31.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 6.49 | 1.8 | 2.8 | 2.4 | |||||||||||
income-statement-row.row.gross-profit | 36.32 | 41 | 23.1 | 29.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 41.8 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 16.85 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.operating-expenses | 55.04 | 56.9 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 55.04 | 58.7 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.interest-income | 1.85 | 1.9 | 0.7 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 3.94 | 1.8 | 8.2 | 3.7 | |||||||||||
income-statement-row.row.ebitda-caps | 3.87 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -30.74 | -15.8 | -43.5 | -51.8 | |||||||||||
income-statement-row.row.income-before-tax | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
income-statement-row.row.income-tax-expense | 12.28 | 0 | -2 | -2.4 | |||||||||||
income-statement-row.row.net-income | -23.67 | -24.5 | -31.3 | -43.4 |
Ofta ställda frågor
Vad är Pieris Pharmaceuticals, Inc. (PIRS) totala tillgångar?
Pieris Pharmaceuticals, Inc. (PIRS) totala tillgångar är 38680000.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 20819000.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.848.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -43.657.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är -0.553.
Vad är företagets totala intäkter?
Totala intäkter är -0.718.
Vad är Pieris Pharmaceuticals, Inc. (PIRS) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är -24543000.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 0.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 56873000.000.
Vad är företagets kassaflöde?
Företagets kassa är 17396000.000.